Alembic Pharmaceuticals, a Rs.1,450 crore plus Vadodara based pharma company, has received minor setback during the third quarter ended December 2012 due to lower export sales of APIs. Its net sales declined by 3.3 per cent to Rs.368.80 crore from Rs.381.33 crore in the corresponding period of last year. Its net profit, however, improved by 9.1 per cent to Rs.48.27 crore from Rs.44.23 crore on account of lower interest burden and higher other income. Its EBDITA improved by 6.1 per cent to Rs.72.82 crore from Rs.68.61 crore.

The company's domestic formulations sales improved by 15 per cent to Rs.228 crore from Rs.199 crore. The chronic and acute segments grew by 23 per cent and 4 per cent respectively. It launched a dermatology division in current year. Its domestic sales of APIs increased to Rs.24.99 crore from Rs.18.73 crore while APIs export declined sharply to Rs.42 crore from Rs.89.90 crore in the similar period of last year. International generic formulation sales moved up to Rs.61.05 crore from Rs.58.45 crore in the last period. It filed 6 ANDAs taking cumulative ANDA and NDA filings of the company to 55. Cumulative ANDA approvals now stands at 21.

For the nine months period ended December 2012, Alembic's net sales increased by 1.7 per cent to Rs.1141 crore from Rs.1122 crore in the corresponding period of last year. Its net profit improved by 10.7 per cent to Rs.121.60 crore from Rs.109.83 crore and EBDITA by 5.9 per cent to Rs.190.24 crore from Rs.179.61 crore. Its EPS worked out to Rs.6.45 as against Rs.5.83 in the last period.